Research programme: lactose intolerance therapeutic - Celprogen
Alternative Names: CEP 801Latest Information Update: 28 May 2019
At a glance
- Originator Celprogen
- Class Bacteria
- Mechanism of Action Glycosylceramidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Lactose intolerance
Most Recent Events
- 28 May 2019 No recent reports of development identified for preclinical development in Lactose intolerance in USA
- 23 Apr 2015 Preclinical trials in Lactose intolerance in USA (Unspecified) before April 2015